RIPK2 and Blau syndrome: Indeed, RIPK2 is an attractive drug target for many inflammatory conditions, particularly for inflammatory conditions of the gut, such as Crohn’s disease and inflammatory bowel disease, as well as early onset sarcoidosis, Blau syndrome, inflammatory breast cancer, and multiple sclerosis [53–55].